NOT KNOWN FACTS ABOUT AI FOR LITERATURE REVIEW

The emergence of early IO therapy in the rNSCLC Area has supplied an opportunity to treat micrometastatic illness and boost the immune response when bulk tumour and tumour antigens are current, and it has resulted in a lift in the efficacy with the neoadjuvant treatment method approach, relative to neoCT, as demonstrated by CM816 [nine,32,fifty fiv